1. Home
  2. DBI vs CNTX Comparison

DBI vs CNTX Comparison

Compare DBI & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Designer Brands Inc.

DBI

Designer Brands Inc.

HOLD

Current Price

$7.26

Market Cap

138.7M

ML Signal

HOLD

Logo Context Therapeutics Inc.

CNTX

Context Therapeutics Inc.

HOLD

Current Price

$1.61

Market Cap

116.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DBI
CNTX
Founded
1991
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
138.7M
116.7M
IPO Year
1991
2021

Fundamental Metrics

Financial Performance
Metric
DBI
CNTX
Price
$7.26
$1.61
Analyst Decision
Hold
Strong Buy
Analyst Count
2
8
Target Price
$7.25
$5.67
AVG Volume (30 Days)
1.1M
1.6M
Earning Date
12-09-2025
11-05-2025
Dividend Yield
2.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,892,654,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$0.49
52 Week High
$8.75
$2.00

Technical Indicators

Market Signals
Indicator
DBI
CNTX
Relative Strength Index (RSI) 52.06 65.96
Support Level $7.64 $1.46
Resistance Level $8.35 $1.79
Average True Range (ATR) 0.54 0.17
MACD -0.13 0.02
Stochastic Oscillator 23.33 56.59

Price Performance

Historical Comparison
DBI
CNTX

About DBI Designer Brands Inc.

Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Share on Social Networks: